Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

345. Stimulator of interferon genes(STING)-associated vasculopathy with onset in infancy Disease details / Clinical trials / Drug dev / DR info /

Clinical trials : 5 / Drugs : 3 - (DrugBank : 1) / Drug target genes : 2 - Drug target pathways : 37

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Baricitinib
   Eli Lilly and Company
      2020   Phase 2/Phase 3   NCT04517253   Japan
      2012   -   NCT01724580   United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
      -   Phase 2   EUCTR2015-003424-31-GB   France;United Kingdom;United States
   Masaki Takeshi
      2020   Phase 2-3   JPRN-jRCT2031200152   -
LY3009104
   Eli Lilly and Company
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
      -   Phase 2   EUCTR2015-003424-31-GB   France;United Kingdom;United States
Olumiant
   Eli Lilly and Company
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan